A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma
Inhibition of histone deacetylase (HDAC) provides a potential target for cancer treatment.
Histones are components of the core proteins of nucleosomes, and acetylation and
deacetylation of these proteins play a role in the regulation of gene expression. HDAC
activity is known to be increased in many types of malignant cells; HDAC inhibitors have
been shown to induce differentiation, cell cycle arrest, and apoptosis in cultured tumor
cells. Since this tumor-associated mechanism is common to many types of cancer, HDAC may
have a broad role in cancer treatment.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To Evaluate the Efficacy of LBH589 in the Treatment of Patients With Refractory Clear Cell Carcinoma, as Measured by Progression-free Survival
John D. Hainsworth, M.D.
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI GU 49
|Florida Cancer Specialists||Fort Myers, Florida 33901|
|Northeast Georgia Medical Center||Gainesville, Georgia 30501|
|Baton Rouge General Medical Center||Baton Rouge, Louisiana 70821-2511|
|Methodist Cancer Center||Omaha, Nebraska 68114|
|Peninsula Cancer Institute||Newport News, Virginia 23601|
|Center for Cancer and Blood Disorders||Bethesda, Maryland 20817|
|Tennessee Oncology, PLLC||Clarksville, Tennessee 37043|
|Oncology Hematology Care||Cincinnati, Ohio 45242|
|Hematology Oncology Associates of Northern NJ||Morristown, New Jersey 07960|
|Chattanooga Oncology Hematology Associates||Chattanooga, Tennessee 37404|